Federated Hermes, Inc. Atreca, Inc. Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $4,124 - $8,593	-2,644 Reduced 29.93%	6,191 $11,000
Q1 2022 May 13, 2022	BUY	$1.61 - $5.2 $54 - $176	34 Added 0.39%	8,835 $28,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $25,258 - $55,358	8,801 New	8,801 $27,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $974,978 - $1.8 Million	-198,570 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $1.55 Million - $2.74 Million	198,570 New	198,570 $1.69 Million
Q1 2021 May 13, 2021	SELL	$13.0 - $19.34 $3,588 - $5,337	-276 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$13.03 - $17.09 $794 - $1,042	-61 Reduced 18.1%	276 $4,000
Q3 2020 Nov 12, 2020	BUY	$12.67 - $23.19 $4,269 - $7,815	337 New	337 $5,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.